Effect of a community heart failure clinic on uptake of β blockers by patients with obstructive airways disease and heart failure

被引:27
作者
Shelton, RJ [1 ]
Rigby, AS [1 ]
Cleland, JGF [1 ]
Clark, AL [1 ]
机构
[1] Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull, Yorks, England
关键词
D O I
10.1136/hrt.2004.059758
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the pattern of beta blocker prescribing over one year in a heart failure clinic with a structured approach towards initiation and dose titration and to give a real life perspective on beta blocker use, compliance, and target dose achievement. Methods: Data were retrospectively analysed on 513 consecutive patients regularly attending a community heart failure clinic over a year. Systolic dysfunction was determined from two dimensional echocardiography ( left ventricular ejection fraction <= 40%) and lung function was assessed by spirometry. All patients were considered for b blocker initiation and dose up titration. Results: Within one year 157 patients died. 143 patients started beta blockers resulting in 315 (88%) patients taking beta blockers at one year; 38% were taking the target dose. 124 had evidence of airways obstruction at baseline, 100 (81%) of whom were taking beta blockers at one year. Forced expiratory volume in one second (1.1 v 1.5 l, p< 0.01) and forced vital capacity (2.3 v 2.5 l/min, p = 0.2) were not reduced in patients with airways obstruction who received beta blockers. Daily doses of beta blockers at one year did not differ statistically between patients with obstructive and patients with non-obstructive spirometry results. 12 patients discontinued beta blockers and 14 required dose reduction due to side effects. Conclusion: The majority of patients with heart failure and obstructive airways disease can safely tolerate low dose initiation and gradual up titration of beta blockers.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 37 条
[1]  
[Anonymous], COCHRANE LIB, DOI [10.1002/14651858.CD003566, DOI 10.1002/14651858.CD003566]
[2]   Improving guideline adherence -: A randomized trial evaluating strategies to increase β-blocker use in heart failure [J].
Ansari, M ;
Shlipak, MG ;
Heidenreich, PA ;
Van Ostaeyen, D ;
Pohl, EC ;
Browner, WS ;
Massie, BM .
CIRCULATION, 2003, 107 (22) :2799-2804
[3]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[4]   Tolerability to β-blocker therapy among heart failure patients in clinical practice [J].
Butler, J ;
Khadim, G ;
Belue, R ;
Chomsky, D ;
Dittus, RS ;
Griffin, M ;
Wilson, JR .
JOURNAL OF CARDIAC FAILURE, 2003, 9 (03) :203-209
[5]   Outpatient adherence to beta-blocker therapy after acute myocardial infarction [J].
Butler, J ;
Arbogast, PG ;
BeLue, R ;
Daugherty, J ;
Jain, MK ;
Ray, WA ;
Griffin, MR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (09) :1589-1595
[6]   The evidence for β blockers in heart failure -: Equals or surpasses that for angiotensin converting enzyme inhibitors [J].
Cleland, JGF ;
McGowan, J ;
Clark, A ;
Freemantle, N .
BRITISH MEDICAL JOURNAL, 1999, 318 (7187) :824-825
[7]   Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey [J].
Cleland, JGF ;
Cohen-Solal, A ;
Aguilar, JC ;
Dietz, R ;
Eastaugh, J ;
Follath, F ;
Freemantle, N ;
Gavazzi, A ;
van Gilst, WH ;
Hobbs, FDR ;
Korewicki, J ;
Madeira, HC ;
Preda, I ;
Swedberg, K ;
Widimsky, J .
LANCET, 2002, 360 (9346) :1631-1639
[8]   The heart failure epidemic: exactly how big is it? [J].
Cleland, JGF ;
Khand, A ;
Clark, A .
EUROPEAN HEART JOURNAL, 2001, 22 (08) :623-626
[9]  
FENSTER PE, 1983, CLIN CARDIOL, V6, P125, DOI 10.1002/clc.4960060305
[10]   COMPARATIVE EFFECTS OF CELIPROLOL, PROPRANOLOL, OXPRENOLOL, AND ATENOLOL ON RESPIRATORY-FUNCTION IN HYPERTENSIVE PATIENTS WITH CHRONIC OBSTRUCTIVE LUNG-DISEASE [J].
FOGARI, R ;
ZOPPI, A ;
TETTAMANTI, F ;
POLETTI, L ;
RIZZARDI, G ;
FIOCCHI, G .
CARDIOVASCULAR DRUGS AND THERAPY, 1990, 4 (04) :1145-1149